Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Kallelse till årsstämma i Diagonal Bio AB

Aktieägarna i Diagonal Bio AB (publ), org.nr 559248-8984, (”Bolaget”) kallas härmed till årsstämma tisdagen den 11 juni 2024 kl. 13.00. Stämman hålls på Medicon Village, Scheeletorget 1 i Lund.Rätt att delta och anmälan Aktieägare som önskar delta i årsstämman ska · vara införd i den av Euroclear Sweden AB förda aktieboken fredagen den 31 maj 2024, och · anmäla sitt deltagande så att denna är Bolaget tillhanda senast tisdagen den 4 juni 2024. Anmälan om deltagande ska göras skriftligen till Diagonal Bio AB, Medicon Village, Scheeletorget 1, 223 81 Lund eller per e-post till agm@

Read original

Diagonal Bio AB announces last day of trading in BTU and first day of trading in TO 1

Diagonal Bio AB's ("Diagonal Bio" or the "Company") rights issue of units, with a subscription period ending on April 22, 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTU (paid subscribed unit) is 13 May 2024, and the stop day is 15 May 2024. The first day of trading in warrants of series TO 1 is 17 May 2024.In April 2024, Diagonal Bio carried out a rights issue which provided the Company with approximately SEK 18 million before issue costs. The rights issue has now been registered at the Swedish

Read original

Diagonal Bio AB announces outcome of rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. The subscription period in Diagonal Bio AB’s (“Diagonal Bio” or “the Company”) rights issue of units ended on the 22nd of April 2024. The rights

Read original

Diagonal Bio AB publish – White paper

Diagonal Bio’s platforms using an 8-parallel test format, show overall Accuracy of 99.6 %, Sensitivity of 100 %, and Specificity of 99.5 %.Diagonal Bio publishes its latest white paper describing the technology and specifications of its the LAMPlify® and Panviral® platforms for pathogen detection in a user-centric, 8-parallel test format. The platform technology taps into the ultra-fast speed and convenience of the Loop-mediated Isothermal Amplification (LAMP), and the specificity and robustness of Electrochemical detection. As a part of Diagnostic Performance Evaluation of the LAMPlify®

Read original

Diagonal Bio AB strengthens its go-to-market strategy through an agreement with founding partner Johan Källstrand

Diagonal Bio AB (publ) ("Diagonal Bio" or the "Company") today announces a strategic step to strengthen its sales and marketing efforts. The company has secured the commitment of Johan Källstrand, one of the company's founders with extensive experience and knowledge within the company's market areas. The agreement means that Diagonal Bio is supported by Källstrand's long experience and deep knowledge to strengthen its go-to-market strategy.Johan Källstrand, with a background and deep knowledge of Diagonal Bio's products, technologies, and market, will play a central role in the sales team

Read original

The subscription period in Diagonal Bio AB rights issue commences today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Today, the 8[th] of April 2024, the subscription period in Diagonal Bio AB’s ("Diagonal Bio" or "the Company") issue of units consisting of shares

Read original

Diagonal Bio announces successful pilot study results and extended partnership with Hørsholm Veterinary Clinic

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces the extension of its partnership with Hørsholm Veterinary Clinic following the successful completion of a three-month pilot study. The pilot study was focused on utilizing Diagonal Bio’s platform technology, LAMPlify®, for the detection of viral infections in horses. The successful results were validated by an independent external laboratory in Germany, underscoring the efficacy and reliability of the LAMPlify® analysis system.The pilot study tested Diagonal Bio’s LAMPlify® technology on a series of samples from horses

Read original

Diagonal Bio AB publishes a prospectus because of upcoming rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.Diagonal Bio AB ("Diagonal Bio" or the "Company") announced on the 28[th] of February 2024 that the board, subject to approval by the extraordinary

Read original

Bulletin from the Extraordinary General Meeting on Tuesday 2[nd] of April in Diagonal Bio AB

Today, 2[nd] April 2024, an Extraordinary General Meeting was held in Diagonal Bio AB, reg. no. 559248–8984. Below is a summary of the resolutions passed. All resolutions were passed with the required majority.The board's proposal on reducing the share capital (Item 7)The general meeting decided on the board of directors' proposal to reduce the company's share capital in accordance with the conditions below: 1. The purpose of the reduction is to allocate to unrestricted equity.2. The company's share capital shall be reduced by 1,998,788.95 SEK.3. The reduction shall be carried out

Read original

Diagonal Bio appoints Karin Wehlin as new CEO

Diagonal Bio AB (publ.) (“Diagonal Bio” or “the Company”) is pleased to announce that the Board of Directors has appointed Karin Wehlin as Chief Executive Officer (CEO) of Diagonal Bio. Karin Wehlin is currently Diagonal Bio’s interim CEO.Karin Wehlin was elected to the Board of Directors of Diagonal Bio in the spring of 2023, and on November 23, 2023, she was appointed as interim CEO. Karin holds an Executive MBA degree from Lund University and has completed education at INSEAD in Strategy, Innovation, and Leadership. She has over 25 years of experience in senior positions within the Life

Read original

Notice to attend the extraordinary general meeting of Diagonal Bio AB

Shareholders in Diagonal Bio AB, 559248-8984, are hereby invited to attend an extraordinary general meeting on Tuesday, 2nd of April, 2024, at 13:00 CET at The Spark, conference room 10, Medicon Village, Scheeletorget 1 Lund.Right to Participate and Notification Shareholders who wish to participate at the extraordinary general meeting must: · be registered as a shareholder in the share register maintained by Euroclear Sweden AB on Thursday, March 21[st], 2024, and · notify the company no later than Monday, March 25[th], 2024, by email to egm@diagonalbio.com. Notifications can

Read original

The Board of Directors decides on a preferential rights issue of units in order to finance future development

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.The Board of Directors of Diagonal Bio AB ("Diagonal Bio" or the "Company") has today, on February 28, 2024, resolved to carry out an issue of units

Read original

Diagonal Bio AB Year-end Report 2023

“Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as the CE-marking of LAMPlify® according to Low Voltage Directive (LVD) 2006/95/ EC. A highlight of our fourth quarter was the commencement of LAMPlify® commercialisation.” says, Karin Wehlin, interim CEO Diagonal Bio AB.Summary of Year-end Report 2023 2023-10-01 — 2023-12-31 (October — December) • Net sales amounted to 23 KSEK (0 KSEK), capitalised development contributed with 405 KSEK (846 KSEK), while other operating income amounted to 7 KSEK (3

Read original
There are no items matching the current filter
There are no more items matching the current filter
Back to top